Clinical Trials Logo

Reflux Esophagitis clinical trials

View clinical trials related to Reflux Esophagitis.

Filter by:

NCT ID: NCT03214081 Active, not recruiting - Reflux Esophagitis Clinical Trials

Special Drug Use Surveillance of Takecab for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

Start date: March 1, 2016
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of long-term administration of Vonoprazan tablets (Takecab tablets) when used as maintenance therapy for reflux esophagitis in routine clinical settings.

NCT ID: NCT03116841 Recruiting - Reflux Esophagitis Clinical Trials

Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

VISTAEXE
Start date: August 9, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to exploratorily evaluate the effect of vonoprazan 20 mg on sleep disturbance of patients with reflux esophagitis, who have heartburn and/or regurgitation and ≥ 6.0 in the Pittsburgh Sleep Quality Index (PSQI) global score despite the maintenance treatment with PPI other than vonoprazan.

NCT ID: NCT02513784 Active, not recruiting - Barrett's Esophagus Clinical Trials

Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome

Mouthwash
Start date: August 2015
Phase: N/A
Study type: Interventional

This is a randomized, open-label pilot study to assess whether treatment with chlorhexidine mouthwash can alter the esophageal and gastric cardia microbiome

NCT ID: NCT02477475 Completed - Reflux Esophagitis Clinical Trials

Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes

Start date: July 7, 2015
Phase: N/A
Study type: Observational

The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.

NCT ID: NCT02288728 Not yet recruiting - Quality of Life Clinical Trials

Double Tract Anastomosis and Gastric Tube Anastomosis to Proximal Gastrectomy

DTA&GTA
Start date: December 2014
Phase: Phase 3
Study type: Interventional

Gastric cancer as one of the most common gastrointestinal cancers, radical resection of primary lesions combined with dissection of regional lymph-nodes is acknowledged by surgeons all over the world. When compared with the advanced upper third gastric cancer, proximal gastrectomy has been acknowledged as the standard therapeutic strategy for the early gastric cancer located in the upper third of the stomach. However, due to abandon the anti-reflux barrier of the digestive system caused by the dissection of the cardia and the lower esophageal sphincter, the belching、hiccup、Acid reflux、heartburn、chest pain symptoms and as well as the reflux esophagitis caused by the traditional esophagostomy permanently influence the postoperative quality of life for those patients. Nowadays, relationship between the digestive track reconstruction for proximal gastrectomy and the postoperative quality of life is still with controversies. Previous study reported the gastric tube anastomosis can minimize the reflux related symptoms when compared with traditional esophagogastrostomy. There still exited some patients need long-term anti-acid drug to control the reflux symptoms although underwent the gastric tube anastomosis. The double-track anastomosis for proximal gastrectomy may successfully control the reflux symptoms and there existed study found it is as safe as the esophagostomy. But there has no randomized control study to compare the postoperative quality of life between the gastric tube anastomosis and double-track anastomosis for proximal gastrectomy. By the reasons above, a randomized controlled trial is conducted with the intention to compare the intraoperative and postoperative mortality and morbidity and the postoperative quality of life between the esophagogastrostomy and the double-track anastomosis in the proximal gastrectomy for gastric cancer patients.

NCT ID: NCT01964131 Completed - Gastric Ulcer Clinical Trials

BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects

Start date: October 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is; To investigate whether a D961H sachet 20 mg is bioequivalent to a D961H HPMC capsule 20 mg by the assessment of percentage of time with intragastric pH>4. To compare a D961H sachet 20 mg with a D961H HPMC capsule 20 mg by the assessment of percentage of time with intragastric pH>3 during 24 hours and 24-hour median pH. To compare PK properties of a D961H sachet 20 mg with those of D961H HPMC capsule 20 mg. To evaluate the safety and tolerability of a D961H sachet 20 mg and D961H HPMC capsule 20 mg.

NCT ID: NCT01860482 Completed - Reflux Esophagitis Clinical Trials

The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

Start date: April 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.

NCT ID: NCT01733810 Active, not recruiting - Clinical trials for Gastroesophageal Reflux Disease

The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis

Start date: February 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the role of hypoxia inducible factor (HIF)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.

NCT ID: NCT01560598 Not yet recruiting - Reflux Esophagitis Clinical Trials

Adipokines and the Risk of Reflux Esophagitis

Start date: June 2012
Phase: N/A
Study type: Observational

We aimed to risk faoctors for GERD and association between visceral obesity, plasma adipoline(leptin, adiponectin, IL-6, TNF-α)and development of reflux esophagitis in healthy Koreans.

NCT ID: NCT01538849 Completed - Reflux Esophagitis Clinical Trials

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.